Trending...
- T. Jones Group's Cameron Jones Serves as Judge for the 2026 CHBA National Awards for Housing Excellence
- $29.8 Million Record Setting Q1 with Boosted Annual Guidance to $160 Million for Expanding Pre-Owned Boat Dealer: Off The Hook YS, Inc. N Y S E: OTH
- SRK Collective Media Group Launches with a Modern Approach to Media, Authority Building, and Cultural Visibility
MORRISVILLE, N.C.--(BUSINESS WIRE)--Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB). Dr. Cavagnaro is an internationally recognized expert in science-based regulatory strategies and translation of research to preclinical and product development, with an emphasis on genetic medicines.
"We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics," said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. "Joy's expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases."
Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Society's 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.
More on ncarol.com
"Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome," said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. "This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need."
About Life Edit Therapeutics Inc.
Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.
More on ncarol.com
Contacts
Investor Contact:
Catherine Hu
chu@elevate.bio
Life Edit Media Contact:
Courtney Heath
courtney@scientpr.com
"We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics," said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. "Joy's expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases."
Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Society's 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.
More on ncarol.com
- CCHR Highlights Concerns Over Coercive and Failed $140 Billion Mental Health Practices at Psychiatric Convention
- Avery Headley Leads Major Stabilization and Modernization Initiative Across Bronx Affordable Housing Portfolio
- America's Boating Channel® Releases New Video Explaining Give-Way and Stand-On Vessel Navigation Rules
- NewReputation's AI Sentiment Analysis Tool Reaches 2,500 Users as Businesses Demand Clearer Brand Intelligence
- Sunday Best Winner Tasha Page-Lockhart Headlines A'Leurer's 1-Year Anniversary Celebration in Greensboro
"Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome," said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. "This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need."
About Life Edit Therapeutics Inc.
Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.
More on ncarol.com
- CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
- $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
- New from Regal House Publishing, Margery and Me, based on the true story of psychic Margery Crandon
- Fyt-02 Launches on Kickstarter The Smart Sensor That Turns Any Chair Into a Posture & Movement Track
- YieldOMega Launches $DOUB Airdrop Campaign Ahead of TimeCurve Launch
Contacts
Investor Contact:
Catherine Hu
chu@elevate.bio
Life Edit Media Contact:
Courtney Heath
courtney@scientpr.com
0 Comments
Latest on ncarol.com
- TAYP Expands Athlete Exposure Platform Beyond Georgia With New Push Into Virginia and the 757
- KT Medical Staffing Expands Concierge Nursing and Private Duty Nursing Services in Orange County
- The Millennium Alliance Achieves Great Place To Work® Certification™ Amid Continued Growth
- The Millennium Alliance Appoints Former Adweek Executive Eric Hayden Shakun as Chief Financial Officer to Accelerate Next Phase of Growth
- T. Jones Group Named Finalist Across Multiple Categories at the 2026 Georgie Awards
- Rock & Roll Fan Granted Dream Experience Thanks to Donors and Grant A Dream™ Program
- The Simplest Small Business You're Probably Not Thinking About
- San Francisco Writer Wins Webby Award, Internet's Highest Honor, for Website Based on her Novel
- EDC Weekend Comedy Special Featuring Don Barnhart & Friends — Use Promo Code FRIEND for 50% Off
- N Y S E: OTH Off The Hook YS Is Building a Vertically Integrated Marine Empire — And Investors Are Starting to Notice
- Concierge Title Agency Merges with Independence Title, Inc. to Deliver an Expanded Concierge Closing Experience Across South Florida
- Grow My Security Company Launches Next-Generation Website and Expands Strategic Marketing Solutions for the Security Industry
- $4.8M in Contracted AI Revenue with Projections of $30M Over 6-12 Months for Diversified AI Software and Platform-Based Services Provider XMax Inc
- Michelangelo's Great Secret Hiding in Plain Sight
- From Blank Page to Published Book
- Virginia Marchese's Paradox: A Nation Still Deciding Who Belongs Examines Race, Migration, Law, and America's Unfinished Struggle for Equality
- Larry R. Wasion's Jump Gate III RoadMaker Blends Cutting-Edge Sci-Fi with High-Stakes Space Exploration and Complex Technologies
- American Mensa and Davidson Institute Join Forces To Strengthen Support for Profoundly Gifted Youth
- SpeedyIndex Rolls Out Automated API for Mass URL Verification, Solving the Backlink Blind Spot for SEO Agencies
- Unto These Hills Outdoor Drama Returns for 76th Anniversary Season Beginning May 30th